Combining gemcitabine treatment with an anti-IL17A antibody could be an effective strategy to regulate the function and activity, such as the metabolism of macrophages, by attenuating typical M1 and M2 metabolic pathways and elicit antitumor responses, particularly in cases of pancreatic cancer where gemcitabine is frequently used [15]. The gene discussed is IL17A; the disease is familial pancreatic carcinoma.